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Structural Basis for E2-Mediated SUMO Conjugation
Revealed by a Complex between
Ubiquitin-Conjugating Enzyme Ubc9 and RanGAP1
Saccharomyces cerevisiae Smt3 was the first SUMO
ortholog to be identified (Meluh and Koshland, 1995).
Smt3 modification appears critical for septin ring forma-
tion, chromosomal segregation, and progression of the
cell cycle through G2-M (Johnson and Blobel, 1999; Ta-
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kahashi et al., 1999; Tanaka et al., 1999; Li and Hoch-New York, New York 10021
strasser, 1999). Mammals contain three known SUMO2 Department of Biochemistry and Molecular
proteins that include classical SUMO-1 and two others,Biology
SUMO-2 and SUMO-3, that share roughly 50% se-Bloomberg School of Public Health
quence identity with SUMO-1. We will use SUMO toJohns Hopkins University
describe the system and refer by name to protein com-Baltimore, Maryland 21205
ponents.
Several SUMO-conjugated proteins have been identi-
fied that modulate critical cellular pathways. Sumoyla-Summary
tion of mammalian RanGAP1 occurs on Lys526, a modi-
fication required for nucleocytoplasmic transport andE2 enzymes catalyze attachment of ubiquitin and ubi-
for its association with Nup358 (RanBP2) at the nuclearquitin-like proteins to lysine residues directly or
pore complex (Matunis et al., 1996; Mahajan et al., 1997).through E3-mediated reactions. The small ubiquitin-
IB sumoylation occurs on Lys21, the same residuelike modifier SUMO regulates nuclear transport, stress
targeted for ubiquitination, thus protecting IB fromresponse, and signal transduction in eukaryotes and
degradation, a process that leads to NFB nuclear trans-is essential for cell-cycle progression in yeast. In con-
location (Desterro et al., 1998). Sumoylation of p53trast to most ubiquitin conjugation, the SUMO E2 en-
Lys386 does not directly protect it from ubiquitination,zyme Ubc9 is sufficient for substrate recognition and
but enhances p53 transcriptional activity through alysine modification of known SUMO targets. Crystallo-
mechanism that remains unclear (Rodriguez et al., 1999;graphic analysis of a complex between mammalian
Gostissa et al., 1999). PML, PML-RAR, and SP100 nu-Ubc9 and a C-terminal domain of RanGAP1 at 2.5 A˚
clear localization (Kamitani et al., 1998; Sternsdorf etreveals structural determinants for recognition of con-
al., 1997), centromere segregation (Tanaka et al., 1999),sensus SUMO modification sequences found within
and septin ring formation (Johnson and Blobel, 1999;SUMO-conjugated proteins. Structure-based mutagen-
Takahashi et al., 1999) are among several other path-esis and biochemical analysis of Ubc9 and RanGAP1
ways modulated by SUMO conjugation, indicative of areveal distinct motifs required for substrate binding
large and varied role for this process in the cell (Melchior,and SUMO modification of p53, IB, and RanGAP1.
2000).
The mechanisms utilized to attach ubiquitin and ubi-Introduction
quitin-like modifiers to cellular proteins share many simi-
larities and some important differences. All Ub/Ubl con-Ubiquitin (Ub) and ubiquitin-like (Ubl) modifiers are100
jugation results in isopeptide bond formation betweenamino acid proteins that modulate protein function
a protein lysine  amino group and the Ub/Ubl modifierthrough posttranslational covalent attachment to lysine
C terminus (Hershko and Ciechanover, 1998). Full-lengthresidues within targeted proteins. The Ub/Ubl-conju-
Ub/Ubl is first proteolytically processed at its C ter-
gated state of proteins has been linked to critical cellular
minus, producing the conserved Ub/Ubl C-terminal dig-
pathways including differentiation, apoptosis, the cell
lycine (Gly-Gly) motif. The Ub/Ubl C terminus is then
cycle, and responses to stress (Muller et al., 2001; Mel- adenylated by E1 enzymes and transferred to a con-
chior, 2000; Hershko and Ciechanover, 1998; Hochstras- served E1 cysteine to form an E1-Ub/Ubl thioester ad-
ser, 1996; Laney and Hochstrasser, 1999; Saitoh et al., duct. The Ub/Ubl-E1 thioester is subsequently trans-
1997). SUMO-1 (small ubiquitin-related modifier; also ferred to a conserved cysteine within E2. E2 then utilizes
known as PIC1, UBL1, Sentrin, GMP1, and Smt3) is a the energy stored in the thioester bond to enable Ub/
member of the ubiquitin and ubiquitin-like superfamily. Ubl transfer to E3 molecules or to directly conjugate the
Although SUMO-1 shares some sequence and structural Ub/Ubl modifier to a lysine amino group within a protein
similarity to ubiquitin, the cellular functions for each target.
family are unique. Ubiquitinated proteins are generally Ubiquitin conjugation utilizes unique combinations of
polyubiquitinated and targeted to the 26S proteosome numerous E2 and E3 factors to direct catalysis and en-
for degradation (Hershko and Ciechanover, 1998). Su- sure specificity during conjugation (Hershko and Cie-
moylated substrates are not generally polysumoylated, chanover, 1998). In contrast, Ubc9 is the only known
nor are they targeted for degradation. SUMO modifica- SUMO E2 enzyme (Seufert et al., 1995; Johnson and
tion alters target protein function through changes in Blobel, 1997), and Ubc9 is apparently sufficient for
activity, cellular localization, or protection from ubiquiti- SUMO conjugation since all identified substrates can
nation. be specifically modified in vitro using only E1, Ubc9,
mature SUMO, and ATP. Interestingly, recent reports
identified two yeast E3-like ring finger proteins, Siz13 Correspondence: lima@pinky.med.cornell.edu
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and Siz2, that enhance E2-mediated sumoylation of the 573–576, residues observed in helical conformation in
the first crystal form. The structure has been refined toseptins (Johnson and Gupta, 2001; Takahashi et al.,
2001), and another report identified an E3-like ring finger an R factor and Rfree of 0.223 and 0.301, respectively. A
section of simulated annealing omit map electron den-protein PIAS that enhanced p53 sumoylation (Kahyo et
al., 2001). Siz1, Siz2, and PIAS proteins are related by sity is presented in Figure 1 (Brunger et al., 1998; Table
1; see Experimental Procedures).sequence and have been assigned the SP-ring acronym,
for Siz-PIAS-ring finger motifs (Hochstrasser, 2001). The
identified SP-ring factors do not alter Ubc9 specificity, Structures of Ubc9 E2 and RanGAP1
suggesting that these E3s regulate SUMO conjugation A structure for human Ubc9 has been described (Tong
by increasing affinity between Ubc9 and substrate. et al., 1997). We also crystallized and determined the
Most SUMO-modified proteins contain the tetrapep- structure for human Ubc9 at 2.0 A˚ by molecular replace-
tide motif -K-x-D/E where  is a hydrophobic residue, ment. This model was used to dock Ubc9 into the experi-
K is the lysine conjugated to SUMO, x is any amino acid, mental RanGAP1-Ubc9 electron density prior to refine-
and D or E is an acidic residue. The observed consensus ment and manual rebuilding. Ubc9 and other ubiquitin
motif within SUMO conjugation targets is unique since E2 family members encode a similar fold and active site
similar consensus sequences have not been uncovered cysteine. Briefly, most E2 enzymes contain an N-ter-
in ubiquitin conjugation pathways. Substrate specificity minal  helix followed by a five- to seven-stranded 
appears to be derived directly from Ubc9 and the re- sheet, the loop containing the catalytic cysteine, fol-
spective substrate motif since no other cofactors are lowed by three C-terminal  helices (Figures 2A and
needed in vitro to observe Ubc9 catalytic specificity. 2B). Ubc9 does not undergo significant conformational
Structural data has not been available for any ubiquitin changes in complex with RanGAP1 (0.69 A˚2 root mean
or SUMO conjugating enzyme-substrate complex, high- square deviation [rmsd] over amino acids 3–158 to un-
lighting a significant gap in our understanding for ubiqui- complexed Ubc9). The largest differences observed oc-
tin and ubiquitin-like modifier transfer from E2 or E3 cur in helix C, a region in direct contact with RanGAP1.
enzymes to a substrate lysine. To determine the molecu- The C-terminal domain of mammalian RanGAP1 has
lar basis for E2-dependent transfer mechanisms and not been previously reported, although the structure
to elaborate interactions utilized by Ubc9 for substrate for the S. pombe RanGAP1 N-terminal domain has
recognition and catalytic activity, we have structurally been solved (Hillig et al., 1999). Vertebrate and fungal
characterized a complex between Ubc9, the SUMO con- RanGAP1 proteins share roughly 35% sequence identity
jugating enzyme, and RanGAP1. Structure-based muta- in their N-terminal domain, but differ because yeast
genesis of the Ubc9-RanGAP1 interface combined with RanGAP1 orthologs do not contain the C-terminal do-
assays for p53, IB, and RanGAP1 SUMO conjugation main that is sumoylated and required for RanGAP1 local-
have enabled Ubc9-substrate interactions to be general- ization at the vertebrate nuclear pore complex.
ized, highlighting a critical and central role for the SUMO The RanGAP1(420–589)p structure reveals a domain
motif in Ubc9-mediated conjugation. composed almost entirely of helical substructures with
one noted exception, the peptide containing the lysine
required for SUMO conjugation. The SUMO consensusResults and Discussion
motif is observed in extended conformation between
helices F and G (Figure 2C). A structural homologyStructure Determination of the Ubc9-RanGAP1
search calculated with DALI (Holm and Sander, 1993)Complex
revealed similarities to 100 amino acid helical-repeatHuman Ubc9 and a C-terminal fragment of mouse
domains sharing 6%–12% sequence identity toRanGAP1(420–589)p were purified to isolate a complex
RanGAP1 from proteins such as clathrin assemblypreviously characterized as a minimal functional domain
lymphoid myeloid leukemia protein, the h-ras fragmentfor E2-SUMO conjugation (Sampson et al., 2001). Sele-
(p21) of son of sevenless-1, protein phosphatase pp2a,nomethionine-substituted protein was isolated, crystal-
karyopherin -1, and pumilio, among many others. Nonelized, and used in a 3 wavelength MAD experiment to
share sequence or structural homology with the Ran-obtain phases (Hendrickson, 1991). A single complex
GAP1 SUMO motif, indicating architectural rather thancrystallized per asymmetric unit (ASU) (83% solvent con-
functional significance to these similarities. PFAM andtent). This facilitated density modification and produced
PSI-Blast, programs that rely heavily on sequenceinterpretable electron density (Table 1; see Experimental
search algorithms, did not uncover these relationships.Procedures).
A model for Ubc9 and RanGAP1 was built and refined
to 2.8 A˚ to an R factor and Rfree of 0.30 and 0.36, respec- Structure of the RanGAP1-Ubc9 Complex
Elucidation of the Ubc9-RanGAP1 complex revealedtively. A second crystal form was identified in the interim
that diffracted anisotropic X-rays to 2.3 A˚. The model several critical interactions between Ubc9 and RanGAP1
that included the molecular basis for Ubc9 recognitionwas used in molecular replacement calculations with the
second data set (two complexes per ASU) and refined to of the RanGAP1 -K-x-D/E consensus motif. Although
continuous, the interface between RanGAP1 and Ubc92.5 A˚. The second crystal form contained an inter-
complex disulfide bridge between Ubc9 Cys138 and can be most simply described in two parts. The first
includes interactions between RanGAP1 helices H andRanGAP1 Cys575 (from complex 1 to 2 and 2 to 1).
These bonds did not affect changes in Ubc9 or the F and Ubc9 surfaces emanating mainly from helix C.
The second part includes interactions between the con-interface between Ubc9 and RanGAP1, although it did
result in structural perturbations for RanGAP1 residues sensus RanGAP1 sumoylation motif (-LKSE-) and Ubc9
Structural Analysis of a Ubc9-RanGAP1 Complex
347
Table 1. Crystallographic Data
Reflections
Resolution (A˚) Wavelength (A˚) (Unique/Total) Coverage (%) (I/) Rsyma
25–2.8 0.9793 (edge) 50,956/678,527 84.8 (67.7) 10.4 (2.5) 0.102 (0.43)
25–2.8 0.9788 (peak) 48,413/551,627 80.5 (60.0) 10.4 (2.8) 0.085 (0.42)
25–2.8 0.9712 (remote) 48,072/554,374 80.1 (60.5) 9.7 (2.7) 0.090 (0.44)
25–2.5 0.9790 (native) 27,902/274,090 96.2 (92.2) 12.0 (3.1) 0.080 (0.34)
Anomalous Diffraction Ratiosb (25–2.8 A˚) FOMc (25–2.8 A˚)
Edge Peak Remote
Edge 0.102 (0.241) 0.052 (0.175) 0.063 (0.189) SOLVE (Acentric/Centric) 0.28 (0.10)/0.24 (0.10)
Peak 0.111 (0.237) 0.057 (0.169) RESOLVE (Acentric/Centric) 0.53 (0.24)/0.58 (0.17)
Remote 0.107 (0.248)
Refinement (25–2.5 A˚)
Number of reflections  0.0 27,248 Rms deviationsd
Nonhydrogen atoms Bond length (A˚) 0.007
Protein 4,932 Bond angles () 1.30




MAD data completeness treats Bijvoe¨t mates independently. Numbers in parentheses indicate outer shell statistics.
a Rsym 	 
|I  I|/
I, where I is the observed intensity, I is the average intensity.
b Anomalous diffraction ratios 	 |F|2  1/2, where |F| is the absolute value of the Bijvoe¨t (diagonal elements) or dispersive difference (off
diagonal elements).
c Figure of merit 	 |F(hkl)best|/F(hkl)
d Root mean square deviations from ideal geometry and B factors for bonded atoms.
e Rcryst R based on 95% of the data.
f Rfree R based on 5% of the data withheld for crossvalidation.
surfaces that include the catalytic cysteine, strands 6 surface area (1.4 A˚ probe radius), accounting for 9%
of the total area calculated for the two molecules aloneand 7, and the loop preceding helix C (Figures 2, 3,
and 4). (Nicholls et al., 1991). The RanGAP1 SUMO consensus
motif is extruded from the helical domain, enabling sim-The complex buries roughly 1500 A˚2 of total accessible
ple calculation of accessible surface area buried by the
SUMO motif. Leu525 to Glu528 was deleted from
RanGAP1, and 460 A˚2 of buried accessible surface area
was lost. The calculation was repeated for Ubc9 and
the tetrapeptide motif, resulting in 550 A˚2 of buried ac-
cessible surface area, roughly one-third of the total. A
detailed description of these interactions follows.
Ubc9 Recognition of the SUMO Consensus Motif
Almost all sumoylated proteins contain the tetrapeptide
motif -K-x-D/E, where  is a hydrophobic residue, K
is the lysine to which SUMO is conjugated, x is any amino
acid, and D or E is an acidic residue. The RanGAP1
consensus peptide (525–528) is observed in extended
-like conformation, although hydrogen bonding pat-
terns to the peptide main chain do not support this
configuration directly. The motif begins with the hy-
drophobic residue (Leu525 in RanGAP1). Leu525 side
chain atoms are observed in VDW contact with atoms
from Ubc9 residues Pro128, Ala129, Gln130, and Ala131.
These interactions are not extensive since this Ubc9
surface is flat, indicating that hydrophobic residues at
the  position do not fit lock-and-key into a conserved
pocket (Figure 4). Rather, sequence conservation at po-
sition 1 likely arises from exclusion of hydrophilic resi-Figure 1. Electron Density Map for the RanGAP1-Ubc9 Complex
dues, an observation supported by the diversity of hy-Simulated annealing omit map (1.0) centered on RanGAP1 Lys526
drophobic side chains located at this position (Melchior,(top left) and Ubc9 Cys93 (bottom left). Figures generated with
SETOR unless noted (Evans, 1993). 2000).
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Figure 2. Ubc9 and RanGAP1 Ribbon Diagrams and Ubc9-E2 Sequence Alignment
(A) Ubc9 ribbon diagram and secondary structure assignment. Helices are lettered, strands are numbered. Cys93 is in solid bonds. N and C
termini are denoted in italics.
(B) Structure-based sequence alignment for human Ubc9, zebra fish Ubc9, hamster Ubc9, Drosophila Ubc9, and S. cerevisiae Ubc9 and
sequences for human Ubc1, Ubc2, Ubc3, UbcH5b, Ubc7, and UbcH10. Sequence identity is in blue shading, similarity is in yellow shading.
Red and black dots over sequence indicate Cys93 and mutants, respectively. Numbering is for human Ubc9. Ubc9 secondary structure is
indicated by arrows (strands numbered) and bars (helices lettered), as in (A).
(C) Ribbon diagram and secondary structure assignment for the C-terminal domain of RanGAP1. SUMO motif residues Leu525, Lys526, and
Glu528 are in solid bonds.
The second residue of the motif is lysine, the strictly Side chains at the third consensus motif position are
not conserved. The extended conformation of the pep-conserved amino acid that serves as the acceptor for
SUMO and as the nucleophile during attack at the Ubc9- tide directs this amino acid side chain away from the
surface of Ubc9. Although sequence conservation atSUMO thioester. Lys526 is observed in a shallow groove
created by backbone atoms from Ubc9 residues the third position is low, a space between the lysine at
position 2 and the acidic residue at position 4 would beAsp127, Pro128, and Ala129 and side chain atoms from
Ubc9 Asp127 and Tyr87 (Figures 4 and 5). The groove required, serving to saddle the consensus peptide over
Tyr87 through VDW interactions between Ser527 mainis mainly hydrophobic, comprised largely by interactions
between aliphatic Lys526 side chain atoms and the chain atoms and side chain atoms from Tyr87.
The fourth position in the motif is almost always anTyr87 aromatic ring. Asp127 and RanGAP1 Lys526 are
within 2.7 A˚ hydrogen bonding distance, suggesting a acidic glutamate side chain, although some identified
sites contain Asp or Asn, and more rarely, Pro. RanGAP1catalytic role for Asp127 in Lys526 coordination during
attack at the SUMO-Ubc9 thioester. The Lys526 N atom Glu528 is observed within hydrogen bonding distance
of Ser89 (2.5 A˚), Thr91 (3.0 A˚), and more distantly withis also 2.6 A˚ away from an ordered water molecule and
3.5 A˚ away from the S atom of the Ubc9 Cys93. Lys74 (3.6 A˚) (Figure 4). Hydrophobic VDW interactions
Structural Analysis of a Ubc9-RanGAP1 Complex
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Figure 3. Ribbon and Stereo Diagrams for
Ubc9-RanGAP1.
(A and B) Orthogonal ribbon representations
with helices lettered and strands numbered,
as in Figure 2. Ubc9 Cys93 and RanGAP1
Leu525, Lys526, and Glu528 are in solid
bonds. N and C termini are denoted in italics.
(C) Stereo image of the complex, as in (A).
are observed between Tyr87 and the aliphatic chain a general base or an environment that could specifically
abstract a proton from the acceptor lysine. The Ubc9-of Glu528, interactions that could partially explain the
preference for the longer glutamic acid side chain at SUMO thioester is extremely labile under physiological
conditions, suggesting a suitably unstable bond thatthis position. Amino acids immediately preceding and
following the motif are not in contact with Ubc9, sug- could facilitate direct transfer to the weakly nucleophilic
lysine, if properly positioned, without involvement ofgesting that the -K-x-D/E motif is sufficient for Ubc9
modification. Structure and sequence-based mutagene- other catalytic residues, thus resulting in the relatively
stable isopeptide bond between the modifier and ac-sis used to test these observations will be discussed
below. ceptor lysine.
RanGAP1 Lys526, the nucleophile and acceptor for
SUMO, is within hydrogen bonding distance of Cys93,Implications for SUMO and Ubiquitin Transfer
The active site observed in Ubc9 shares many similari- the catalytic Ubc9 cysteine, indicating that Lys526 is in
an appropriate configuration to attack the E2-Ub/Ublties with those observed in other E2-conjugating en-
zymes and could thus serve as a model for other E2- thioester during conjugation. Several residues near
Cys93, such as Asp127, Asn85, and Tyr87, contain func-substrate interactions. A commonly invoked mechanism
for Ub/Ubl conjugation involves a general base that acti- tional groups consistent with catalytic function. Several
of these residues have been mutated (see below), andvates the nucleophilic acceptor lysine for ubiquitin and
SUMO transfer. Residues surrounding the Ubc9 cata- none completely block activity, indicating nonessential
catalytic roles for most of these side chains. Conservedlytic cysteine and RanGAP1 acceptor lysine, while coor-
dinating the orientation of these residues, do not provide side chains in E2 alignments mostly occur in the hy-
Cell
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Figure 4. Stereo Images of Ubc9-RanGAP1
Interaction
(A and B) Orthogonal orientations of the Ran-
GAP1 consensus motif in complex with Ubc9.
Amino acids are indicated by type, number,
or both. Ubc9 Glu98 and Asp100 are removed
in (B).
(C) RanGAP1-Ubc9 interaction outside the
motif recognition interface. Helices lettered
for RanGAP1 (F and H) and Ubc9 (C). Back-
bone positions are represented by ribbon
spline (RanGAP1 in yellow, Ubc9 in blue), the-
oretical hydrogen bonds are dotted lines, and
waters are red spheres.
drophobic core and in loops that likely stabilize the fold complex (data not shown), suggesting that amino acid
residues between Ubc9 helix B and C, as well as resi-(Figure 2B). Other conserved motifs suggestive of cata-
lytic function include the HPN sequence motif observed dues in the loop preceding Cys93, may play a role in
coordinating an extended C-terminal diglycine motif.at positions 83–85 and the less strictly conserved EPN
motif at positions 122–124. Although untested, these The SUMO-Ubc9 complex proposed in our model is
supported by recent NMR experiments that resolved aregions appear to play primarily structural rather than
catalytic roles. The HPN motif is involved in extensive thioester complex between Ubc1 and ubiquitin (Hamil-
ton et al., 2001). These studies indicate the channel mayside chain to main chain hydrogen bonding networks
that form a scaffold within a channel implicated in coor- be utilized to coordinate the Gly-Gly motif and that helix
B is a central element in E2-ubiquitin interaction. Com-dination of the SUMO or ubiquitin diglycine motif (see
below), and residues 122–124 are not located near the paring Ubc9-RanGAP1 to other E2-E3 or E2-E2 com-
plexes (E6AP-UbcH7, c-Cbl-UbcH7, and Mms2/Ubc13)catalytic cysteine, but are near helices B and C, another
area potentially involved in ubiquitin or SUMO inter- also supports this orientation for SUMO or ubiquitin in
the complex (Huang et al., 1999; Zheng et al., 2000;action.
The Ubc9-RanGAP1 complex reveals a platform and VanDemark et al., 2001). These models, when taken to-
gether, utilize extensive E2 surfaces in their interactionsunique position for the acceptor lysine within the Ubc9
catalytic site, suggesting a position for the SUMO while leaving open a large surface that could be available
for ubiquitin or SUMO interaction (Figure 5E). Interest-C terminus and thioester adduct between Cys93 and
Asp127, near the water molecule coordinated by Lys526 ingly, E2 surfaces occluded in complexes with RanGAP1,
Mms2, and collective E3s (E6AP and Cbl) are uniquein Figure 4B. A channel is formed between the receptor
peptide and Ubc9, one large enough to accommodate and nearly nonoverlapping, suggesting that several of
these complexes could occur simultaneously, consis-the Gly-Gly motif found at the end of all ubiquitin and
ubiquitin-like modifiers (Figures 5A and 5B). A similar tent with a role for E3-mediated E2-substrate interaction
(Figures 5C–5E).channel has been observed in the crystal structure of
Smt3, the yeast SUMO ortholog, in complex with the
yeast desumoylating enzyme Ulp1 (Mossessova and Functional Characterization of RanGAP1
SUMO conjugation assays have been utilized to probeLima, 2000). Smt3 coordinates (47% identical to human
SUMO-1) were manually docked into the Ubc9-RanGAP1 structure-function relationships between RanGAP1 and
Structural Analysis of a Ubc9-RanGAP1 Complex
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Figure 5. Models for Ubc9 Surfaces Utilized in Substrate, SUMO, E2, and E3 Binding
(A) Surface and bond representations for Ubc9 and the RanGAP1 SUMO tetrapeptide motif, respectively. Ubc9 Asp127 (red), Cys93 (green),
and Tyr87 (pink) are indicated on the Ubc9 surface. The location of the channel discussed in the text is indicated by a yellow arrow.
(B) Orthogonal view of (A). RanGAP1 Lys526 N atom is visible beyond the yellow arrow.
(C–E) Orthogonal Ubc9 surface representations in complex with RanGAP1, Mms2, E6AP, and Cbl. The RanGAP1 SUMO motif is represented
by solid bonds, RanGAP1(420–589)p as a red worm, the Cbl ring finger as a light blue worm, the E6AP Hect domain as a dark blue worm,
and Mms2 as a green worm. Surface area buried in respective complexes is shown as a red surface (RanGAP1), a green surface (Mms2), and
a blue surface (E6AP and Cbl, combined). E2s from each complex were aligned to Ubc9 by least-squares minimization on C atoms. Figures
5 and 7 were prepared with GRASP (Nicholls et al., 1991).
endogenous SUMO-conjugating enzymes (Sampson et SUMO motif, and several residues in helix H (Figures
6A, 7C, and 7D).al., 2001). Results from that study combined with further
structure-based mutagenesis from this study reveal mu- L524A disrupts sumoylation, and although Leu524
does not interact with Ubc9 directly, it likely anchorstations in the sumoylation motif and in helix H that dra-
matically disrupt sumoylation. RanGAP1 mutations with the RanGAP1 consensus motif (525–528) within its hy-
drophobic core, thus stabilizing the conformation of theno observable defects in conjugation included residues
in helix F, residues stabilizing the conformation of the SUMO motif. L525A probably disrupts hydrophobic
Cell
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Figure 6. SDS-PAGE Analysis for SUMO Conjugation and Product Formation Utilizing Wild-Type and Mutant RanGAP1 and Ubc9
(A) RanGAP1 SUMO conjugation assay by endogenous conjugating enzymes with mutant and wild-type RanGAP1.
(B) RanGAP1(420–589)p SUMO conjugation using wild-type and mutant Ubc9.
(C) p53(320–393)p SUMO conjugation using wild-type and mutant Ubc9.
(D) IB SUMO conjugation using wild-type and mutant Ubc9. Wild-type and mutant enzymes are denoted by WT or mutation (i.e., C93S for
cysteine to serine at residue 93). Panels in (B)–(D) were constructed with cut-outs from several Coomassie-stained SDS-PAGE gels containing
respective sumoylation products (see Experimental Procedures).
VDW interactions between Ubc9 and RanGAP1, al- design 19 mutations covering Ubc9 surfaces that in-
cluded most of the Ubc9 catalytic and binding motifs.though alanine has been observed at this position in
at least two confirmed SUMO targets (Melchior, 2000). Mutants were expressed, purified, and assayed in
SUMO conjugation assays over several time points withK526A and K526R both disrupt sumoylation by removal
of the acceptor lysine, although K526R still exhibited the C-terminal domain of RanGAP1 (Figures 2B, 6B, and
7B; see Experimental Procedures).wild-type binding affinities for Ubc9. E528A mutation
also disrupts SUMO transfer, and as explained pre- Mutation of the active site cysteine (C93S) diminished
conjugation to an undetectable level, likely through dis-viously, the glutamic acid makes VDW contacts with
Tyr87 and is within hydrogen bonding distance to Ubc9 ruption of E1-E2 SUMO transfer. Although some serine
substituted E2s function in E1 modifier transfer, we haveLys74, Ser89, and Thr91. These mutations reveal an
essential role for the consensus motif during Ubc9- determined that C93S mutation blocks efficient SUMO
transfer between E1 and Ubc9 at physiological pH (datamediated conjugation.
F564A and K567A reveal critical interactions between not shown). Ubc9 mutants such as Q139A and S89AT91A
exhibited nearly wild-type activity in RanGAP1 conjuga-RanGAP1 and Ubc9 that are distant from direct interac-
tions with the consensus SUMO motif and indicate tion assays. Gln139 is located at the periphery of the
interface (light blue in Figure 7B). The S89AT91A mutantRanGAP1 adaptations to increase Ubc9 interaction (Fig-
ure 4C). F564A is predicted to disrupt hydrophobic inter- was more active than either S89A or T91A alone, sug-
gesting the formation of a less restrictive hydrogen-actions between Phe564 (helix H) and Ubc9 Ala131 and
Tyr134 (helix C). K567A would disrupt interactions be- bonding network that could enable other productive
binding configurations.tween the Lys567 N atom and the backbone carbonyl
oxygen of Ubc9 Gln126 (3.4 A˚), as well as VDW interac- Several Ubc9 mutants did not exhibit wild-type rates
for accumulation of sumoylated substrate but were suffi-tions with Pro128 and Tyr134. These mutations, com-
bined with the structural analysis, reveal a large interface cient for conjugation within the time course (blue in
utilized in RanGAP1-Ubc9 interaction, suggesting that Figure 7B). Glu98 and Asp100 are located on the loop
RanGAP1 has developed additional binding surfaces for between strand 7 and helix B and are in a position to
Ubc9 that may substitute directly for an E3-like cofactor. interact with substrates approaching the active site.
Lys74, Ser89, and Thr91 interact with RanGAP1 Glu528
of the consensus motif, and Y134F, T135A, and T135LFunctional Characterization of Ubc9
To assess Ubc9-substrate recognition, interactions ob- are all located between Ubc9 helix C and RanGAP1 helix
H (Figure 4C).served in the Ubc9-RanGAP1 complex were used to
Structural Analysis of a Ubc9-RanGAP1 Complex
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Figure 7. Surface Views of the Ubc9-Ran-
GAP1 Interface
(A) Ubc9 surface and worm model for Ran-
GAP1, buried Ubc9 surface area colored blue.
RanGAP1 Leu525, Lys526, and Glu528 are in
solid bonds.
(B) As in (A), except surface area color-coded
to represent the Ubc9-RanGAP1 mutational
analysis. Color-coded bar between (B) and
(D) indicates activity levels from light blue (ac-
tive) to red (inactive). These include Q139
(light blue); K74, S89, T91, E98, and D100
(blue); D127, E132, and T135 (yellow); Y87,
P128, A129, A131, and Y134 (pink); and C93
(red).
(C) RanGAP1 surface and Ubc9 worm de-
picting buried RanGAP1 surface area (blue).
(D) As in (C), but with RanGAP1 mutants de-
picted by color. L524, L525, K526, E528,
F564, and K567 (red for inactive); N512, T516,
R517, I520, H521, M522, D529, I531, L537,
L560, A563, and N569 (light blue for active).
(E) Ubc9 surface with RanGAP1 SUMO motif
L-K-S-E in solid bonds with buried Ubc9 sur-
face area colored blue.
(F) As in (E), but with Ubc9 mutational analysis
from p53 conjugation represented as surface
colors. Color-coded bar shown between (F)
and (G) indicates activity levels from green
(hyperactive) to red (inactive). Residues in-
clude E98 and D100 (green); E132, Y134,
T135, and Q139 (light blue); K74, S89, and
A131 (pink); and Y87, T91, C93, D127, P128,
and A129 (red).
(G) Color-coded mutational analysis for IB
conjugation as in (F). Residues include E98,
D100, E132, Y134, and T135 (light blue); Q139
(blue); K74 and A131 (yellow); and Y87, S89,
T91, C93, D127, P128, and A129 (red).
Two mutations, Y87F and D127A, were designed to observed for Y87F and D127A suggest they are not es-
sential catalytic residues for RanGAP1 conjugation.assess catalytic roles for the tyrosine hydroxyl or as-
partic acid carboxylate. Y87F would eliminate the ty- Several mutations exhibited detrimental effects on
RanGAP1 SUMO conjugation (pink in Figure 7B). E132Arosine hydroxyl while preserving the hydrophobic aro-
matic contacts observed between Tyr87 and RanGAP1 and Y134A likely disrupt interactions between helix C
and RanGAP1 helices H and F (Figure 4C). Mutation ofLys526, Ser527, and Glu528. Asp127 is in direct contact
with Lys526 through a hydrogen bonding or salt-bridg- Pro128, Ala129, and Ala131 also diminish SUMO conju-
gation of RanGAP1. These residues are all located ining interaction, potentially coordinating the lysine for
attack at the thioester adduct (Figure 4). The activities the loop preceding helix C that directly interacts with
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RanGAP1 residues Leu525 and Lys526. Pro128 is con- in this region have little to no effect on SUMO conjuga-
tion of IB and p53, suggesting that IB and p53served throughout the E2 family and is likely required
at this position for its unique structural attributes (Figure do not interact with Ubc9 through the same interface
utilized by RanGAP1.2B). A129C probably disrupts VDW interactions between
Ubc9 and the substrate lysine by altering the backbone Ubc9 mutations that dramatically decrease IB and
p53 SUMO conjugation include residues predicted toconfiguration at this position. Comparison between
Y87A and Y87F reveals a significant contribution made make direct contact with the consensus -K-x-D/E mo-
tif, as observed in the Ubc9-RanGAP1 structure (Figuresby the aromatic ring to activity, interactions that include
VDW contacts with the K-x-D/E portion of the SUMO 4 and 7E–7G). Though not critical for RanGAP1 sumoyla-
tion, Asp127 is required for effective IB and p53 su-motif. No single Ubc9 mutation other than C93S com-
pletely inhibited SUMO conjugation, suggesting that moylation, probably due to its direct contact with the
acceptor lysine, one that likely positions the lysine forresidues probed by our mutagenesis are not essential
for catalytic activity. These results are consistent with attack at the thioester adduct. Tyr87 contacts the K-x-
D/E portion of the motif through VDW interactions withthe proposed model that excludes a specific E2 general
base for activation of the catalytic lysine during conju- each of these residues, and substitution of the side
chain to alanine effectively blocks conjugation. Ala129gation.
contacts the acceptor lysine through VDW contacts,
and both Pro128 and Ala131 provide VDW surfaces forComparison between RanGAP1, IB, and p53
interaction with the residue of the motif. Lys74, Ser89,To assess general motifs utilized in Ubc9 substrate inter-
and Thr91 all interact with the acidic residue of the -K-actions and to enable a comparative analysis between
x-D/E motif, and each is required for full activity.respective Ubc9-substrate pairs, Ubc9 mutants were
Ubc9 residues observed in direct contact with theevaluated in SUMO conjugation assays with two other
RanGAP1 SUMO motif are apparently more critical forsubstrates, full-length human IB and the C-terminal
Ubc9 interaction with p53 and IB, as the Ubc9 surfacetetramerization domain from human p53 (see Experi-
area buried by this motif is almost perfectly coveredmental Procedures). The RanGAP1 sumoylation motif
by the detrimental mutations that affect p53 and IBoccurs between secondary structural elements (Figures
SUMO conjugation (Figures 7E–7G). E2 enzymes known2 and 3). In contrast, sumoylation motifs within IB
to conjugate ubiquitin to IB Lys21 share some se-(DGLKKERL) and p53 (LMFKTEGP) occur at N- and
quence similarity to Ubc9 within the motif recognitionC-terminal ends of the proteins, respectively. p53
interface. These include Ubc9 residues Tyr87, Thr89,Lys386 is targeted for sumoylation and is located within
and Ala129 for Ubc3 and Ubc9 residues Lys74, Ser91,a C-terminal peptide outside the structured tetrameriza-
and Asp127 for UbcH5b (Figure 2B), indicating that Ubc3tion domain (residues 325–356) (Jeffrey et al., 1995).
and UbcH5b may recognize the peptide containing IBIB Lys21 is targeted for both sumoylation by Ubc9
Lys21 in a similar manner. While speculative and un-and for ubiquitination by UbcH5b, UbcH5c, and Ubc3
tested, these observations can be extended to suggest(Gonen et al., 1999), and it occurs N-terminal to the
that other E2-mediated conjugation reactions coordi-structured ankyrin repeats found in this protein (Huxford
nate their lysine-containing substrates in a manner simi-et al., 1998; Jacobs and Harrison, 1998).
lar to that observed in the Ubc9-RanGAP1 complex.Analysis of SUMO conjugation reactions for p53,
RanGAP1, and IB reveals more similarities than differ-
ences among these substrates with respect to individual Conclusions
We have presented the crystal structure and biochemi-Ubc9 mutations, although conjugation reactions con-
taining IB and p53 more closely resemble each other cal analysis of a complex between Ubc9 and the
C-terminal domain of RanGAP1, the first E2-substratewhen compared to RanGAP1. Taken together, these
results indicate a central role for Ubc9 recognition of the complex observed at atomic resolution. Analysis of the
RanGAP1 C-terminal domain reveals structural similaritySUMO -K-x-D/E motif in Ubc9-substrate interactions.
They also suggest that Ubc9 does not discriminate sig- to proteins with helical repeat motifs, although the func-
tional significance of these relationships with respectnificantly among internal, N-terminal, or C-terminal con-
sensus sites within respective targets. Interestingly, to SUMO conjugation is limited since none contain a
consensus SUMO motif. Analysis of the complex re-some Ubc9 mutants that exhibited activity in RanGAP1
assays were almost completely defective in p53 and vealed extensive RanGAP1 interactions with Ubc9 sur-
faces outside the consensus motif, an adaptation thatIB conjugation, and others that reduced catalytic ac-
tivity in RanGAP1 conjugation did not affect conjugation likely results in increased binding and more effective
SUMO transfer as compared to other known substrates.to p53 or IB (Figures 6B–6D).
Several Ubc9 mutations elicit wild-type activity in The structure revealed key determinants for Ubc9 recog-
nition of the -K-x-D/E consensus sumoylation motifassays with p53 or IB (blue in Figures 7F and 7G),
and some mutations apparently enhance the process that is observed within all known SUMO-modified pro-
teins. Shallow grooves, complementary electrostatic,(E98A and D100A, green in Figure 7F for p53). Although
untested, E98A and D100A could make the surface of and hydrogen bonding interactions created by con-
served residues on the surface of Ubc9 provide a plat-Ubc9 more hydrophobic in character, thus increasing
binding interactions for this enzyme-substrate pair. Mu- form onto which the -K-x-D/E motif is saddled and
specifically recognized, enabling proper orientation andtations in Ubc9 helix C, such as Y134A and E132A, inter-
fere with RanGAP1 SUMO transfer by disrupting a bind- coordination of the acceptor lysine.
The structure and corresponding mutagenesis sug-ing interface between these molecules. Ubc9 mutations
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sodium citrate (pH 5.5) and 5% glycerol, cryoprotected by additiongests that residues surrounding the active site cysteine
of 25% glycerol, and cryopreserved in liquid nitrogen. SeMet crys-are not capable of specifically removing a proton from
tals diffracted X-rays weakly to 2.6 A˚ along the c axis and to 3.0 A˚the acceptor lysine during nucleophilic attack at the
along a and b axes (P3221, a 	 b 	 128.9 A˚, c 	 130.3 A˚,  	  	thioester adduct. Although the acceptor lysine is often 90,  	 120). A second crystal form was obtained from 2.0 M
thought of as a substrate, lysine serves as the nucleo- ammonium phosphate, 0.1 M HEPES (pH 7.0), 10 mM CuCl2, 5%
glycerol (P21212, a 	 86.5 A˚, b 	 126.5 A˚, c 	 72.6 A˚,  	  	  	phile within a three-part enzyme complex that includes
90) that diffracted anisotropic X-rays to 2.3 A˚.the “substrate” and the Ubc9-SUMO thioester, an inter-
Diffraction screening utilized a Cu-K source (Rigaku RU200)mediate analogous to the acyl-enzyme complex thought
equipped with Osmic multilayer optics and a Raxis-IV imaging plateto occur during protease reactions. Since the thioester
detector. Native and MAD data sets were collected at National Syn-
is relatively unstable, the lysine may merely need to chrotron Light Source (Brookhaven, NY) beamline X4A using an
approach the thioester in the correct orientation for at- ADSC Quantum-4 detector. Data was reduced with DENZO,
SCALEPACK (Otwinowski and Minor, 1997) and CCP4 (Collaborativetack, thus eliminating the need for specific removal of
Computational Project, 1994) (Table 1).a lysine proton by E2. Although a lowered pKa for the
MAD data analysis revealed seven selenium sites used to generatenucleophilic lysine cannot be excluded, we do not be-
2.8 A˚ phases (SOLVE and RESOLVE [Terwilliger and Berendzen,lieve that the lysine is activated by a general base, but
1999]). The model was traced using O (Jones et al., 1991) and refined
rather that it is facilitated for attack through proper orien- with CNS (Brunger et al., 1998). Structures for two complexes using
tation with respect to the thioester. the P21212 data set were solved by molecular replacement to 2.5 A˚,
refined without noncrystallographic symmetry, and manually rebuiltStructure-based mutagenesis and SUMO conjugation
into 2FoFc, FoFc, and simulated annealing OMIT maps. The model,assays with Ubc9, IB, p53, and RanGAP1 have re-
having excellent geometry with no Ramachandran outliers, con-vealed a similar mode of interaction between Ubc9 and
tained residues 3–158 for Ubc9 and 434–589 for RanGAP1. Electronrespective -K-x-D/E motifs, suggesting that sub-
density for Ubc9 residues 1 and 2 and RanGAP1 residues 420–433
strates containing this motif will interact with Ubc9 in a were not observed. These regions represent 5% of the structure,
similar manner. While we are not able to exclude addi- possibly contributing to the relative high Rfree value obtained in re-
finement. Coordinates and structure factors are deposited in thetional Ubc9 surfaces utilized for p53 and IB binding,
Protein Data Bank with accession code 1KPS.mutations that fully disrupt p53 and IB sumoylation
exhibit activity against RanGAP1, suggesting that
Mutagenesis and Biochemical AssaysRanGAP1 encodes an additional E3-like binding activity
Point mutations in the C-terminal domain of RanGAP1 were engi-capable of recruiting Ubc9 to its -K-x-D/E motif for
neered into N419/PK (Sampson et al., 2001) using PCR-basedSUMO conjugation. These results are consistent with
mutagenesis. Proteins were translated in rabbit reticulocyte lysate
mechanisms for E2- and E3-mediated conjugation that in the presence of [35S]methionine. SUMO-1 modification by endoge-
utilize SP-ring E3-like proteins to increase activity by nous reticulocyte lysate-conjugating enzymes was determined by
SDS-PAGE and autoradiography. Point mutations in phUbc9 wereenhancing Ubc9-substrate affinities. The structural and
obtained using PCR-based mutagenesis (QuikChange, Stratagene).biochemical results presented here should provide fur-
Mutants were expressed and purified as for wild-type Ubc9 andther groundwork for studies focused on Ubc9 E2-medi-
concentrated to 1 mg/ml in 350 mM NaCl, 20 mM Tris-HCl (pHated SUMO conjugation and, more generally, for studies
8.0), 1 mM DTT. SUMO conjugation was assayed at 37C with
related to substrate recognition by cognate E2 conjuga- RanGAP1(420–589)p using 0.3 M E1, 2 mM ATP, 5 mM MgCl2, 10%
tion enzymes. glycerol, 50 mM Tris (pH 7.5), 2 M RanGAP1, and 2 M mature
SUMO and initiated by adding 0.3 M Ubc9. Samples were removed
at specified times, denatured in SDS-PAGE buffer, and stored atExperimental Procedures
4C or20C until SDS-PAGE analysis and Coomassie blue staining.
p53 and IB SUMO conjugation were assayed identically exceptCloning, Expression, and Protein Purification
that substrate and SUMO concentrations were increased to 50 MHuman UBC9 was amplified from cDNA by PCR, cloned into pET-
and Ubc9 to 3 M. UBC9 mutations were confirmed by DNA se-28b to encode an N-terminal thrombin cleavable hexahistidine
quencing.tagged fusion protein (phUbc9), transformed into E. coli BL21(DE3)-
pLysS (Novagen), and induced with IPTG. Protein was purified by
Ni-NTA-agarose resin (Qiagen), dialyzed against 50 mM Tris-HCl Acknowledgments
(pH 8.0), 200 mM NaCl, 2 mM -mercaptoethanol (BME), and bovine
thrombin (Sigma), and purified by cation exchange (MonoS, Phar- We thank John Buglino, Vincent Shen, and David R. Lima for techni-
macia). Mouse RanGAP1(420–589)p was amplified by PCR and cal assistance and the staff of beamline X4A at the National Synchro-
cloned into a modified pET28b vector containing N-terminal hexahis- tron Light Source, a DOE facility. Beamline X4A is supported by the
tidine-tagged S. cerevisiae Smt3 (pSUMO) (Mossessova and Lima, Howard Hughes Medical Institute. M.J.M. and D.A.S. are supported
2000). Smt3-RanGAP(420–589)p was purified by metal-affinity, cleaved by a grant from the National Institutes of Health (GM60980). V.B.V.
by Ulp(403–621)p, and purified by gel filtration (Superdex 75). acknowledges support from the Secretarı´a de Estado de Educacio´n
Selenomethionyl (SeMet) protein was produced in E. coli DL41 y Universidades of Spain. C.D.L. acknowledges support from the
(Hendrickson et al., 1990). Purified RanGAP1 and Ubc9 were mixed Arnold and Mabel Beckman Foundation.
1:1, purified by gel filtration (Superdex75), and concentrated to 10
mg/ml in 50 mM NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM BME. Coding
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